Shares of Inovio Pharmaceuticals Inc. INO advanced 1.90% to $1.61 Friday, on what proved to be an all-around positive trading ...

Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Inovio Pharmaceuticals (INO) has been beaten down lately with too much selling pressure. While the stock has lost 11.4% over ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. INOVIO (NASDAQ: INO), a biotechnology company focused on ...

Inovio Pharmaceuticals Inc. closed 89.14% below its 52-week high of $13.44, which the company reached on May 16th.

Inovio Pharmaceuticals, Inc.’s INO share price has surged by 10.67%, which has investors questioning if this is right time to sell.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for recurrent respiratory ...